Zacks Investment Research on MSN
Are GLP-1 drugs becoming a meaningful revenue driver for CAH stock?
Cardinal Health CAH is clearly benefiting from the rapid adoption of GLP-1 therapies, though the impact remains more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results